Type 1 diabetes: Medications

Researchers have identified four simple clinical criteria that can be used to predict the likelihood of insulin allergy and guide decisions about the need for confirmatory allergy testing.

Results of a phase 1 study show that a concentrated version of insulin aspart not only provides a smaller injection volume but also has a more rapid onset of action than the standard version.

Implementing a subcutaneous insulin protocol for the treatment of diabetic ketoacidosis significantly reduces intensive care admissions and readmission to hospital within 30 days of discharge without increasing hypoglycemia, research shows.

An extended-wear insulin infusion set, worn for up to 7 days, is more satisfactory to users than standard insulin infusion sets and does not adversely affect glycemic control, shows a study in people with type 1 diabetes.

Moderate- or high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin are the most effective statins for reducing non-high-density lipoprotein cholesterol levels in people with diabetes, study findings indicate.

Subcutaneous mini-dose glucagon reverses hypoglycemia more effectively than oral glucose tablets and helps adults with type 1 diabetes complete Ramadan fasts, shows a randomized crossover trial.

Researchers report that the antihypertensive medication verapamil preserves beta-cell function and reduces insulin needs in adults with type 1 diabetes during up to 2 years of treatment.

The dual Ang-2 and VEGF-A pathway inhibitor faricimab is noninferior to aflibercept for improving visual acuity in people with diabetic macular edema, and an individualized dosing strategy could help reduce treatment burden, suggest findings from the YOSEMITE and RHINE trials.

The proportion of on-target interstitial glucose values falls during the week following initial COVID-19 vaccination in people with type 1 diabetes, study findings indicate.

Findings from the ORACL trial suggest that closed-loop insulin delivery results in better glycemic control than sensor-augmented pump therapy among older adults with longstanding type 1 diabetes.

Fewer than half of older adults receiving a sulfonylurea and/or insulin have their treatment deintensified after an emergency department visit or hospitalization for hypoglycemia, despite guidelines recommending this practice, US research shows.

Insulin degludec offers similar glycemic outcomes to insulin glargine U100, along with more straightforward dosing, for people with insulin-treated diabetes crossing time zones, a small study suggests.

A dual-hormone fully closed-loop system did not demonstrate non-inferiority to a hybrid system in a randomized trial, despite producing a high time in range, report the researchers.

Children and adults with type 1 diabetes achieve significant reductions in glycated hemoglobin and hypoglycemic events during their first 90 days of using the Omnipod DASH insulin pump system, show real-world data.

Randomized trial findings presented at the virtual 57th EASD Annual Meeting suggest that treatment with a high dose of the SGLT2 inhibitor dapagliflozin may improve renal cortical oxygenation in people with type 1 diabetes and albuminuria.

Switching to fast-acting insulin aspart is associated with an increased time in range and reduced glycemic variability, show data from a real-world observational study.

Directing people with insulin-treated diabetes to online education significantly improves their injection technique and glycemic outcomes linked to injecting into lipohypertrophic areas, a study shows.

Using a linear insulin to carbohydrate ratio to determine breakfast insulin requirements leads to significant differences in time in glycemic range and hypoglycemia rates when meal carbohydrate quantities vary, shows a study in children and young adults.

Click through to read more on this announcement

Click through for more information on this FDA approval